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a b s t r a c t
Neuromyelitis optica (NMO) is a rare, disabling, recurring inﬂammatory demyelinating
disease affecting the spinal cord and optic nerves with predominance in women.
We present the case of a female patient with chronic C hepatitis, who, despite treatment,
developed severe symptoms of NMO during pregnancy and postpartum.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Neuromyelitis optica (NMO), also known as Devic's disease, is
a severe, recurring inﬂammatory demyelinating disease affect-
ing the spinal cord and optic nerves. Studies are underway to
understand the etiology of the disease. Current data indicates
that a humoral immune response (NMO-IgG) directed against
aquaporin-4, a water channel protein located in the membrane
of astrocytes, plays a key role in the disease pathogenesis.
Moreover, the high prevalence of NMO in women compared to
men (9:1) suggests that genetic, epigenetic and hormonal
gender-associated factors affect the pathomechanism of the
disease [1]. The ﬁrst symptoms of NMO may be observed in
young women and during pregnancy, when sex hormone levels* Corresponding author at: Department of Neurology, Wrocław Medica
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that the immunological changes occurring during pregnancy
are likely to impact NMO [2]. Therefore, it is important to
recognize the relationship between pregnancy and the disease
course of NMO, which may facilitate the choice of a therapy safe
for both the mother and the child.
The authors present the case of a 37-year old woman with
chronic C hepatitis, who, despite treatment, developed
symptoms of NMO during pregnancy and postpartum.
2. Case report
A 37-year old woman in the 22nd week of pregnancy was
admitted to the Neurology Department with signs of right limb
muscle weakness with an onset a day prior to admission. Sixl University, ul. Borowska 213, 50-556 Wrocław, Poland.
rosół).
p. z o.o. All rights reserved.
Fig. 2 – Cervical and thoracic spinal cord MRI revealed an
extensive T2-weighted hyperintense lesion from level C2
to Th4.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 3 9 7 – 4 0 0398months earlier, the woman was diagnosed at another
neurological care unit for acute bilateral reduction in visual
acuity. At the time, the neurological, ophthalmic examina-
tions and optical coherence tomography (OCT) were normal,
and the cause of the visual deﬁcits was not identiﬁed. Visual
evoked potentials were not recorded. A brain MRI revealed a
few 6 mm large foci corresponding to vascular or demyelinat-
ing lesions. Type IV oligoclonal bands, associated with a
chronic infection with the hepatitis C virus, were identiﬁed in
the serum and cerebrospinal ﬂuid. In addition, the patient was
diagnosed with nodular goiter and hypothyroidism. No causes
of visual impairment were found. A conversion disorder was
considered, and the patient was referred for psychological and
psychiatric consultations. An anti-aquaporin 4 antibody test
was not performed because NMO was not suspected.
The patient was then admitted to our Neurology Depart-
ment. The subsequent neurological examination revealed
right Horner syndrome, converging eyeballs, horizontal-
rotatory nystagmus when looking sideways, bilaterally de-
creased visual acuity (the patient was able to count her ﬁngers
at a distance of 1 m), mild right limb paresis (a score of 4/5 on
the Lovett scale except the right foot muscles, which scored 3/
5), reduced knee and ankle-jerk reﬂexes, the presence of the
Babinski reﬂex in the right foot, and a positive Romberg test.
Sensory disturbances were not found. The patient was able to
walk only with assistance of two people.
Control brain MRI revealed very ﬁne, nonspeciﬁc sites of
hyperintense tissue signal on T2-weighted and FLAIR
sequences indicative of mild perivascular gliosis (Fig. 1).
Cervical and thoracic spinal cord MRI revealed an extensive
T2-weighted hyperintense lesion approximately 15 cm long,Fig. 1 – An MRI brain scan (FLAIR sequence) showing
nonspecific sites of hyperintense tissue signal indicative of
mild perivascular gliosis.
Fig. 3 – Cervical spinal cord MRI at the C6 level revealed
occupied more than half of the spinal cord.extending from level C2 to Th4. It asymmetrically extended in
the spinal cord, mainly occupying the right half of the cord,
including the lateral and posterior funiculus as well as the spinal
cord gray matter on the right. These lesions were most visible at
the C6 level and occupied more than half of the spinal cord. The
primary differential diagnosis provided by the radiologist was a
demyelinating process in the acute/subacute stage (including
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 3 9 7 – 4 0 0 399Devic's disease) (Figs. 2 and 3). The ophthalmic examination
revealed bilateral temporal optic atrophy and atrophy of the
macula lutea. Scotopic and photopic electroretinography (ERG)
response was at the lower limit of the normal range. The latencies
of the visual evoked response (VEP) were increased bilaterally.
Neurography revealed bilateral lumbosacral radiculopathy at the
L4/L5 level with axonal injury of the left peroneal nerve.
Laboratory tests showed a moderate and transient electrolyte
imbalance, hypoalbuminemia, normocytic anemia, a positive
anti-HCV antibody titer, HCV-RNA level was 1,260,000 IU/ml, a
progressive decline in the platelet count (thrombocytopenia in
pregnancy) as well as a positive anti-aquaporin 4 antibody titer
with indirect immunoﬂuorescence technique (IFF). Analysis of
cerebrospinal ﬂuid was within normal limits. Consultations with
a general internal medicine specialist, an infectious disease
specialist, and gynecologist were carried out and abnormalities of
the fetus or pregnancy were ruled out.
The patient was diagnosed with NMO. Plasmapheresis was
introduced and ﬁve cycles of plasma exchange were per-
formed, which resulted in improved muscle strength of the
right limbs, improved gait and visual acuity (the patient was
able to count her ﬁngers at a distance of two meters). Control
laboratory tests indicated an increased platelet count. The
patient was discharged.
Three months after the plasmapheresis (34th week of
gestation) the patient required hospitalization due to a relapse.
The clinical examination revealed a bilateral reduction in
visual acuity (the patient counted her ﬁngers at a distance of
only 1 m), paresis of all four extremities (a score of 4/5 on the
Lovett scale in the upper extremities with ﬂexion contracture
of the right hand digits, a score of 3/5 in the lower left
extremity, a score of 2/5 in the lower right extremity and a
score of 3/5 in the lower left extremity), brisk deep reﬂexes in
the upper right extremity, decreased knee and ankle-jerk
reﬂexes and the presence of the Babinski reﬂex bilaterally. In
addition, the patient had a sacral pressure sore. Periodic limb
contractions were also present. Five consecutive cycles of
plasma exchange were performed. A slight improvement of
the muscle strength in the right limb (3/5) and exacerbation of
the left limb paresis (2/5) were observed.
The woman gave birth to a healthy daughter by cesarean
delivery in the 40th week of gestation (Apgar score of 10).
Lower limb venous thrombosis was present during the
postpartum period. Intravenous infusions of immunoglobu-
lins (140 g in total) and symptomatic treatment were adminis-
tered, which gave slight functional improvement in the lower
limbs. During pregnancy deep venous thrombosis prophylaxis
was used (a low-molecular-weight heparin). Chronic immu-
nosuppression was excluded due to the presence of the sacral
pressure sore and vascular thrombosis. A deferred adminis-
tration of Rituximab was planned. However, the patient did
not return to the neurological care unit following rehabilita-
tion treatment in the Rehabilitation Ward.
3. Discussion
Neuromyelitis optica is a rare disorder characterized by acute
or subacute optic neuritis and subacute cervical or cervi-
cothoracic spinal cord injury. The onset of neurologicalsymptoms and the time interval between them may differ
between patients. In the described case, the ﬁrst symptom of
NMO was loss of visual acuity, which developed prior to
pregnancy. The disease progressed six months later in the 22nd
week of gestation, causing mild right hemiparesis, a minor eye
movement disorder and slight ataxia. One of the main diagnostic
criteria in Devic's disease is the presence of transverse myelitis,
causing para- or tetraparesis [3]. In the described patient, the
disease was diagnosed late due to the time interval between
symptoms of optic nerve damage and spinal cord injury. Cervical
MRI and the detection of antibodies against aquaporin 4 gave
conclusive results, indicative of NMO.
IgG AQP4 autoantibodies, which bind to the aquaporin 4
receptor localized on the end-feet of astrocytes, play a key role
in the pathogenesis of NMO. Their binding activates the
complement system, leading to the deposition of the mem-
brane attack complex in a process known as complement-
dependent cytotoxicity (CDC) [6]. During pregnancy, a number
of homeostatic changes, including immunologic changes that
promote the Th2 humoral response take place [4], which are
most likely associated with an increase in the concentration of
female sex hormones [5]. Increased estrogen levels exert a
multidirectional effect on the immune system. They may
contribute to an increase in the expression of cytidine
deaminase, which is responsible for the production of
immunoglobulins [7]. They may also inﬂuence the changes
in the glycosylation of antibodies [8] modifying their comple-
ment and immunoglobulin Fc receptor binding ability [9].
These mechanisms explain why diseases with a predomi-
nantly Th-2 type cytokine proﬁle are exacerbated during
pregnancy. An increase in the annualized relapse-rate of NMO
was found in the third trimester of pregnancy and in the ﬁrst
trimester postpartum [10]. In the presented patient, there was
a relapse of Devic's disease which began prior to gestation, in
the 22nd and 34th week of pregnancy.
Studies have found that there is a bidirectional relationship
between NMO and pregnancy. Nour et al. [14] reported an
increased incidence of miscarriages mainly in early gestation
despite no signiﬁcant association between the miscarriages
and the IgG-AQP4 titers. In addition, the incidence of
preeclampsia was signiﬁcantly higher in patients with NMO
than in the general population (11.5% vs 3.2%, respectively)
[14]. No such complications were observed in the described
patient, and she gave birth to a healthy daughter.
Clinical data suggest there is a relationship between
immune-mediated nervous system demyelinating processes
and active hepatitis C. It has been shown that HCV contributes
to immune system dysregulation and stimulates B lympho-
cytes to produce antinuclear antibodies (ANA), anti GM1, anti-
sulfatide and anti-neutrophil cytoplasmic antibodies (ANCA)
[15]. The extrahepatic effects of HCV have been reported to
include demyelination of the peripheral nervous system
(multifocal multiple mononeuropathy, crioglobulin-associat-
ed polyneuropathy, chronic inﬂammatory demyelinating
polyradiculoneuropathy) and central nervous system.
Kitadaet al. [16] presented a case of a patient with HCV and
AQP4 antibodies who had central and peripheral nervous
system demyelination. The condition of the patient improved
following sequential treatment with large doses of corticoste-
roids and plasma replacement. Control studies also revealed a
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 3 9 7 – 4 0 0400decrease in the Ig-AQP4 antibody titer. Mariotto et al. [15]
presented a case of a 75-year-old man with chronic C hepatitis
who was diagnosed with Devic's disease based on the clinical
ﬁndings and additional tests (including positive Ig-AQP4
antibody titers). These cases suggest that a HCV infection
may activate the B-lymphocyte production of antibodies
against AQP4 and contribute to Devic's disease.
According to the literature, the main therapy for NMO in
pregnancy is immunosuppression in the form of pulses of
methylprednisolone. Other drugs are administered less fre-
quently [11,17]. Due to the initial mild neurologic symptoms as
well as adverse fetal effects of corticosteroid therapy, together
with an infectious diseases specialist and nephrologist, we chose
to administer plasmapheresis. Studies indicate that plasmaphe-
resis is a safe form of therapy in pregnant women and may be
administered in corticosteroid-resistant relapses of NMO [11].
We obtained signiﬁcant improvement of gait, muscle strength in
the right limbs and a slight improvement of visual acuity.
Intravenous administration of immunoglobulins during the
second disease relapse gave slight clinical improvement reduc-
ing limb paresis. Taking into consideration the disease relapse in
the third trimester of pregnancy and an increased risk of further
exacerbation in the postpartum period, it is advisable to
administer pulses of methylprednisolone followed by an oral
steroid and azathioprine therapy with simultaneous ending of
lactation [13]. However, due to the lower limb thrombosis
following the cesarean section and the presence of a sacral
pressure sore, we did not opt to introduce long-term immuno-
suppressive therapy. Rituximab, which has been reported to be
effective and routinely used to treat NMO, was planned for use in
the patient [18,19]. Rituximab is a monoclonal antibody against
the CD20 antigen found on the surface of B lymphocytes. This
drug has been found to decrease the incidence of disease relapse
and rarely gives serious clinical complications. Ringelstein et al.
[12] described a patient with NMO with antibodies against AQP4
who became pregnant seven months after the administration of
Rituximab. The patient did not experience disease relapse during
pregnancy, and Rituximab was administered two days after
delivery in order to maintain stable neurological results.
4. Conclusion
We present the case of a 37-year old woman diagnosed with
NMO with two disease relapses, causing serious disability.
Coexisting pregnancy and severe complications of the primary
disease (an extensive sacral pressure sore, lower extremity
venous thrombosis) did not permit the introduction of proven
and effective corticosteroid therapy. The patient was treated
with plasmapheresis and intravenous immunoglobulin infu-
sions. The severe course of the disease was most likely caused
by an imbalance in hormones caused by the pregnancy and the
active HCV infection. Together, these factors contributed to
the dominance of humoral immunity, which is fundamental in
the pathogenesis of NMO.
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